SAN ANTONIOILEX Oncology, Inc. has launched the first ILEX-sponsored
study of Campath (alemtuzumab) in patients with CD52-antigen-positive
relapsing or refractory non-Hodgkin’s lymphoma (NHL). Campath is a humanized
monoclonal antibody directed against the CD52 antigen.
The trial, designed to determine the appropriate dose in a weekly
schedule, marks the first time ILEX is studying Campath in a disease in which
the CD52 antigen appears to be highly expressed, the company said in a news
release. Campath is FDA approved for patients with B-cell chronic lymphocytic
leukemia who have been treated with alkylating agents and have failed
fludarabine (Fludara) treatment.